RETRACTED ARTICLE:Inhibition of FoxO1 nuclear exclusion prevents metastasis of Glioblastoma

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 7195-7200

  Chen, Jin ^a   Huang, Qin ^a   Wang, Feng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; FoxO1; Glioblastoma; PI 3 K

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTOR; GELATINASE B; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN TISSUE; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR INVASION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INHIBITORS; FORKHEAD TRANSCRIPTION FACTORS; GLIOBLASTOMA; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84904979333     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1913-1     Document Type: TB

References (29)

1. Schonberg DL, Bao S, Rich JN. Genomics informs glioblastoma biology. Nat Genet. 2013;45:1105-7.
2. Tsatas D, Kanagasundaram V, Kaye A, Novak U. Egf receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci. 2002;9:282-8.
3. Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, et al. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology. 2006;67:872-4. (Pubitemid 44403593)
4. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 2006;3:e6.
5. Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, et al. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet. 2007;172:33-7. (Pubitemid 44920265)
6. Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, et al. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol. 2009;625:23-30.
7. Sjostrom S, Andersson U, Liu Y, Brannstrom T, Broholm H, Johansen C, et al. Genetic variations in EGF and EGFR and glioblastoma outcome. Neuro-Oncol. 2010;12:815-21.
8. Prabhu A, Sarcar B, Kahali S, Shan Y, Chinnaiyan P. Targeting the unfolded protein response in glioblastoma cells with the fusion protein EGF-SubA. PLoS One. 2012;7:e52265.
9. Cornez I, Joel M, Tasken K, Langmoen IA, Glover JC, Berge T. EGF signalling and rapamycin-mediated mtor inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry. J Neurooncol. 2013;112:49-57.
10. Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, Han SY, Li G, Jensen KC, Vogel H, Wei-Xu L, Skirboll SS, Wong AJ. Targeting a glioblastoma cancer stem cell population defined by EGF receptor variant III. Cancer Res 2013.
11. Lee CC, Lai JH, Hueng DY, Ma HI, Chung Y, Sun YY, et al. Disrupting the CXCL12/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma. Cancer Cell Int. 2013;13:85.
12. Liu Q, Li G, Li R, Shen J, He Q, Deng L, et al. Il-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 2010;100:165-76.
13. Papi A, Bartolini G, Ammar K, Guerra F, Ferreri AM, Rocchi P, et al. Inhibitory effects of retinoic acid and IIF on growth, migration and invasiveness in the U87MG human glioblastoma cell line. Oncol Rep. 2007;18:1015-21.
14. Tang ZP, Cui QZ, Dong QZ, Xu K, Wang EH. Ataxia-telangiectasia group D complementing gene (ATDC) upregulates matrix metalloproteinase 9 (MMP-9) to promote lung cancer cell invasion by activating ERK and JNK pathways. Tumour Biol. 2013;34:2835-42.
15. Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S, et al. Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour Biol. 2007;28:247-52. (Pubitemid 350165830)
16. Schutz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, Wittekind C. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol. 2002;23:179-84. (Pubitemid 44858309)
17. Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Cho S, et al. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal. 2009;21:892-8.
18. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2009;218:460-6.
19. Myatt SS, Lam EW. The emerging roles of Forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847-59. (Pubitemid 350006253)
20. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51: 1417-23.
21. Biggs 3rd WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase b/akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor fkhr1. Proc Natl Acad Sci U S A. 1999;96:7421-6. (Pubitemid 29299677)
22. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer. 1994;56:72-7. (Pubitemid 24044796)
23. Tian XX, Chan JY, Pang JC, Chen J, He JH, To TS, et al. Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor. Br J Cancer. 1999;81:994-1001. (Pubitemid 29516143)
24. Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('iressa'). Cancer Lett. 2003;202:43-51. (Pubitemid 37464897)
25. Stish BJ, Oh S, Vallera DA. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neurooncol. 2008;87:51-61.
26. Ozer BH, Wiepz GJ, Bertics PJ. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene. 2010;29:855-64.
27. Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A. 2011;108:15984-9.
28. Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the pTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012;109:14164-9.
29. Zheng Y, Yang W, Aldape K, He J, Lu Z. Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. J Biol Chem. 2013;288:31488-95.